Literature DB >> 11245480

DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

S Jahr1, H Hentze, S Englisch, D Hardt, F O Fackelmayer, R D Hesch, R Knippers.   

Abstract

Increased levels of DNA fragments have frequently been found in the blood plasma of cancer patients. Published data suggest that only a fraction of the DNA in blood plasma is derived from cancer cells. However, it is not known how much of the circulating DNA is from cancer or from noncancer cells. By quantitative methylation-specific PCR of the promoter region of the CDKN2A tumor suppressor gene, we were able to quantify the fraction of plasma DNA derived from tumor cells. In the plasma samples of 30 unselected cancer patients, we detected quantities of tumor DNA from only 3% to as much as 93% of total circulating DNA. We investigated possible origins of nontumor DNA in the plasma and demonstrate here a contribution of T-cell DNA in a few cases only. To investigate the possibility that plasma DNA originates from apoptotic or necrotic cells, we performed studies with apoptotic (staurosporine) and necrotic (staurosporine plus oligomycin) cells in vitro and with mice after induction of apoptotic (anti-CD95) or necrotic (acetaminophen) liver injury. Increasing amounts of DNA were found to be released in the supernatants of cells and in the blood plasma samples of treated animals. A clear discrimination of apoptotic and necrotic plasma DNA was possible by gel electrophoresis. The same characteristic patterns of DNA fragments could be identified in plasma derived from different cancer patients. The data are consistent with the possibility that apoptotic and necrotic cells are a major source for plasma DNA in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245480

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  699 in total

Review 1.  Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Karen-Lise G Spindler; Anders K Boysen; Niels Pallisgård; Julia S Johansen; Josep Tabernero; Morten M Sørensen; Benny V Jensen; Torben F Hansen; David Sefrioui; Rikke F Andersen; Ivan Brandslund; Anders Jakobsen
Journal:  Oncologist       Date:  2017-08-04

2.  Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.

Authors:  Milica Kontic; Jelena Stojsic; Dragana Jovanovic; Vera Bunjevacki; Simona Ognjanovic; Jacquelyn Kuriger; Susan Puumala; Heather H Nelson
Journal:  Clin Lung Cancer       Date:  2011-12-13       Impact factor: 4.785

3.  The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.

Authors:  Zhijun Shen; Chen Chen; Jianhai Sun; Jingsong Huang; Shiguo Liu
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-26       Impact factor: 4.553

4.  A suite of DNA methylation markers that can detect most common human cancers.

Authors:  Lukas Vrba; Bernard W Futscher
Journal:  Epigenetics       Date:  2018-02-19       Impact factor: 4.528

Review 5.  Latest development of liquid biopsy.

Authors:  Alvin Ho-Kwan Cheung; Chit Chow; Ka-Fai To
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 6.  Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.

Authors:  Tian Lu; Jinming Li
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 7.  Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.

Authors:  Aadel A Chaudhuri; Michael S Binkley; Evan C Osmundson; Ash A Alizadeh; Maximilian Diehn
Journal:  Semin Radiat Oncol       Date:  2015-05-15       Impact factor: 5.934

Review 8.  Unleashing the power of proteomics to develop blood-based cancer markers.

Authors:  Ayumu Taguchi; Samir M Hanash
Journal:  Clin Chem       Date:  2012-10-24       Impact factor: 8.327

Review 9.  Extracellular DNA and autoimmune diseases.

Authors:  Hantao Lou; Matthew C Pickering
Journal:  Cell Mol Immunol       Date:  2018-03-19       Impact factor: 11.530

10.  Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Martina Mazzon; Elisa Paviati; Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Silvia Giudici; Ricciarda Raffaelli; Fabio Ghezzi; Massimo Franchi; Giuseppe Lippi
Journal:  Pathol Oncol Res       Date:  2020-05-27       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.